EMEA recommends continued Gardasil use

2 March 2009

The European Medicines Agency (EMEA) says it is unlikely that cervical cancer vaccine Gardasil caused seizures and loss of consciousness in two  girls given the agent in Spain.

The Spanish Ministry of Health temporarily withdrew a batch of the human  papillomavirus vaccine developed by US drug major Merck & Co, following  the emergence of two suspected cases of adverse events (Marketletter  February 16).

The Ministry said that only the NH52670 batch was affected and the move  was only a precaution. At the time, European distributor Sanofi Pasteur  MSD stressed that both children had other medical conditions, which may  have led to the adverse events.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >




Today's issue

Company Spotlight